Virax Biolabs Group (Virax Biolabs Group) Cash, Cash Equivalents, Marketable Securities : $5.11 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Cash, Cash Equivalents, Marketable Securities?

Virax Biolabs Group's quarterly cash, cash equivalents, marketable securities increased from Sep. 2022 ($4.57 Mil) to Mar. 2023 ($9.35 Mil) but then stayed the same from Mar. 2023 ($9.35 Mil) to Sep. 2023 ($5.11 Mil).

Virax Biolabs Group's annual cash, cash equivalents, marketable securities increased from Mar. 2021 ($0.02 Mil) to Mar. 2022 ($0.02 Mil) and increased from Mar. 2022 ($0.02 Mil) to Mar. 2023 ($9.35 Mil).

Virax Biolabs Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Virax Biolabs Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Cash, Cash Equivalents, Marketable Securities Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Cash, Cash Equivalents, Marketable Securities

0.02

9.35

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			0.01	0.02	4.57	9.35	5.11

Virax Biolabs Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Virax Biolabs Group (NAS:VRAX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Virax Biolabs Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.